{"id":462,"date":"2026-09-04T12:19:19","date_gmt":"2026-09-04T10:19:19","guid":{"rendered":"https:\/\/reborn-peptides.com\/knowledge\/mitochondrial-peptides\/"},"modified":"2026-09-04T12:19:19","modified_gmt":"2026-09-04T10:19:19","slug":"mitochondrial-peptides","status":"publish","type":"page","link":"https:\/\/reborn-peptides.com\/en\/knowledge\/mitochondrial-peptides\/","title":{"rendered":"Mitochondrial Peptides: Peptides Encoded Outside the Cell Nucleus"},"content":{"rendered":"<p><strong>Mitochondrial peptides<\/strong> are peptides encoded by open reading frames in mitochondrial DNA and therefore outside the nuclear genome. Humanin, reported in 2001, and MOTS-c, reported in 2015, are the two earliest named representatives covered by this source set. Their shared genetic origin defines a research class; it does not make their structures, experimental roles or measured endpoints interchangeable.<\/p>\n<p>The materials discussed are for laboratory research use only. They are not for human or veterinary use. This page orders the literature by peptide, study model and endpoint. Background on <a href=\"https:\/\/reborn-peptides.com\/en\/knowledge\/what-are-peptides\/\">what peptides are<\/a> and <a href=\"https:\/\/reborn-peptides.com\/en\/knowledge\/\">peptide research basics<\/a> provides the wider laboratory context.<\/p>\n<h2>What makes a peptide mitochondrially encoded<\/h2>\n<p>Mitochondria retain their own DNA. Small open reading frames within that DNA can encode short products that researchers examine as signals. A molecule belongs among mitochondrial derived peptides because of this genomic location, not because of an observed laboratory endpoint. A <strong>mitochondrial-derived peptide<\/strong> must therefore be distinguished from a peptide that merely acts on a mitochondrial process but is encoded elsewhere.<\/p>\n<p>The class description alone does not establish what a peptide does in a cell model, an animal model or a human sample. Those questions require separate evidence. Lee and colleagues identified a 16-amino-acid peptide encoded within mitochondrial 12S rRNA and described its cellular actions as inhibition of the folate cycle and its tethered de novo purine biosynthesis, leading to AMPK activation; the mouse experiments of the same work carried separate organism-level endpoints (Lee 2015, PMID 25738459, DOI 10.1016\/j.cmet.2015.02.009). The length and genomic origin are identity-level facts; the pathway findings remain attached to the models used in that work.<\/p>\n<p>Humanin is a short polypeptide encoded in mitochondrial DNA. Hashimoto and colleagues reported the <strong>humanin peptide<\/strong> in cultured neuronal cells, where the measured endpoint was cell death caused by multiple familial Alzheimer&#8217;s disease genes and by amyloid-beta (Hashimoto 2001, PMID 11371646, DOI 10.1073\/pnas.101133498). That abstract characterises the molecule as a short polypeptide and states no residue count. The cell-model observation is the basis of that report, not a result in people.<\/p>\n<h2>The named members described in the literature<\/h2>\n<p>The named mitochondrial peptides in this source set are listed by the publication year of the cited reports: Humanin, then the 16-amino-acid representative, then the small humanin-like peptides. The table is a class map, not an assertion that each member shares one pathway.<\/p>\n<ul>\n<li><strong>Humanin<\/strong>; 2001; Cultured neuronal cells; cell death endpoint; Hashimoto 2001; PMID 11371646; DOI 10.1073\/pnas.101133498<\/li>\n<li><strong>MOTS-c<\/strong>; 2015; Cell and mouse models; on the cellular level folate cycle, de novo purine biosynthesis and AMPK activation, alongside separate mouse endpoints; Lee 2015; PMID 25738459; DOI 10.1016\/j.cmet.2015.02.009<\/li>\n<li><strong>Small humanin-like peptides (SHLPs)<\/strong>; 2016; Cell models in vitro plus an in-vivo clamp study, species not stated in the abstract; apoptosis, reactive oxygen species and insulin-sensitisation readouts; Cobb 2016; PMID 27070352; DOI 10.18632\/aging.100943<\/li>\n<\/ul>\n<p>Cobb and colleagues reported that an in silico search revealed six additional peptides in the same mtDNA region as Humanin, and named this group the small humanin-like peptides. For SHLP2 and SHLP3 the abstract reports reduced apoptosis, reduced reactive oxygen species and improved mitochondrial metabolism in vitro; for intracerebrally infused SHLP2 it reports clamp readouts consistent with insulin sensitisation. The species used in that clamp study is not stated in the abstract, and inflammatory markers appear in the title without a corresponding result statement (Cobb 2016, PMID 27070352, DOI 10.18632\/aging.100943). A <strong>small humanin-like peptide<\/strong> belongs to that reported series, but similarity of family naming does not establish identical structure or endpoint across the members.<\/p>\n<p>Yen and colleagues later organised discovery and function across mitochondrial-derived microproteins in a review (Yen 2025, PMID 39690001, DOI 10.1016\/j.tig.2024.11.010). That publication synthesises prior literature rather than reporting a new primary experiment. This page does not restate sequences, masses or database identifiers. Where our product records carry such reference values, they describe the molecule and not a supplied batch.<\/p>\n<h2>The mitokine concept<\/h2>\n<p>A mitokine is considered in research as a signal of mitochondrial origin that can communicate an organelle state to other cellular compartments or tissues. The concept describes a proposed signalling function. It is not an intrinsic catalogue attribute, and it does not assign the same signalling route to every member of the class.<\/p>\n<p>This distinction is particularly important for mitochondrial peptides because genetic origin, intracellular location and experimental response are three different evidence layers. Kim and colleagues examined MOTS-c in cellular and molecular models under metabolic stress and observed AMPK-dependent movement into the nucleus together with nuclear gene expression and ARE\/NRF2-related signalling measurements (Kim 2018, PMID 29983246, DOI 10.1016\/j.cmet.2018.06.008). That model-qualified observation illustrates mitochondrial-to-nuclear communication; it does not establish a universal property of the class.<\/p>\n<h2>Signalling routes examined in preclinical models<\/h2>\n<p>Lee and colleagues reported inhibition of the folate cycle and its tethered de novo purine biosynthesis, leading to AMPK activation, at the cellular level; in mice, the same work reported prevention of age-dependent and high-fat-diet-induced insulin resistance and of diet-induced obesity (Lee 2015, PMID 25738459, DOI 10.1016\/j.cmet.2015.02.009). AMPK activation was a molecular readout within the experimental design, and the abstract does not report a phosphorylation measurement. The result cannot be detached from the species, cell system, experimental conditions and comparator.<\/p>\n<p>Kim and colleagues observed AMPK-dependent nuclear translocation under metabolic stress in cellular and molecular models (Kim 2018, PMID 29983246, DOI 10.1016\/j.cmet.2018.06.008). In those models, the authors connected the localisation change with nuclear gene expression and ARE\/NRF2-related contexts. A spatial change in a cell system and an organism-level observation answer different questions.<\/p>\n<p>Yang and colleagues examined C2C12 myotubes and high-fat-diet-induced obese mice given treadmill training. In the myotubes they reported protein and mRNA expression of PGC-1\u03b1 and of MOTS-c itself; in the mice, treadmill training raised protein levels of MOTS-c, PGC-1\u03b1 and GLUT4 together with AMPK and ACC phosphorylation. Glucose metabolism and insulin resistance are named as aims of the work, not as separately reported markers (Yang 2021, PMID 33722744, DOI 10.1016\/j.bbadis.2021.166126). These combined readouts define the study&#8217;s mechanistic scope; they do not demonstrate the same response outside its cell and mouse designs. The distinction among <a href=\"https:\/\/reborn-peptides.com\/en\/knowledge\/study-models\/\">in vitro and animal study models<\/a> should remain part of any laboratory record.<\/p>\n<h2>Endogenous expression under physical exertion<\/h2>\n<p>Reynolds and colleagues combined cell and mouse experiments with a human component. In that human component, exercise induced endogenous expression in skeletal muscle and in circulation (Reynolds 2021, PMID 33473109, DOI 10.1038\/s41467-020-20790-0). Exercise was the intervention there, and the peptide was measured as an endogenously expressed product; the abstract does not state that any peptide was supplied to the participants.<\/p>\n<p>The supplied-peptide intervention and the reported physical-capacity findings of the same publication were in mice (Reynolds 2021, PMID 33473109, DOI 10.1038\/s41467-020-20790-0). Keeping these evidence types separate prevents the human component from changing how the mouse findings are classified. None of the seven cited abstracts reports administration of a supplied research material to people.<\/p>\n<h2>Why the model distinction matters especially here<\/h2>\n<p>One paper can contain several evidence layers. A cultured neuronal cell endpoint, a C2C12 myotube measurement, a mouse intervention and an endogenous measurement in a human sample are not interchangeable simply because each concerns a mitochondrial peptide. The material, model, intervention or tissue, comparator, time point and endpoint must travel with every statement.<\/p>\n<p>Endogenous expression also differs from an experiment using externally supplied material. A measured change in an endogenous peptide after exertion does not establish what a synthetic research material would produce. Likewise, the class membership of <a href=\"\/en\/products\/mots-c\/\">the research material in the catalogue<\/a> makes no statement about that individual material, a batch or an experimental outcome. Purity is supportable only for a tested batch through its <a href=\"https:\/\/reborn-peptides.com\/en\/knowledge\/understanding-the-coa\/\">Certificate of Analysis<\/a>.<\/p>\n<p>The seven sources also serve different functions. Hashimoto 2001, Lee 2015, Cobb 2016, Kim 2018, Yang 2021 and Reynolds 2021 report primary work in their stated models or samples. Yen 2025 is a review. Reading review-level organisation as though it were another experiment would blur both provenance and model boundaries.<\/p>\n<h2>What does not follow from this evidence base<\/h2>\n<p>The cited cell and mouse findings do not establish an outcome in humans. The human component of Reynolds 2021 is an exercise protocol followed by measurement of the endogenously produced peptide; the abstract reports no supplied research material given to people. This evidence base therefore supports neither transfer from mouse or cell systems to people nor transfer from endogenous biology to supplied research material.<\/p>\n<p>AMPK activation, AMPK and ACC phosphorylation, PGC-1\u03b1 expression, GLUT4 protein levels, apoptosis, reactive oxygen species, nuclear gene expression and neuronal cell death are measured laboratory endpoints in the specifically named models. None is a substitute for a different endpoint, and no single marker establishes a class-wide result. The sources also do not establish equivalence among the mitochondrial peptides named here: Cobb 2016 reports that the SHLPs differed from one another in regulating cell viability and that SHLP2 and SHLP3 shared similar protective effects with Humanin, which is a bounded comparison of two members on named endpoints, not a class-wide equivalence covering the 16-amino-acid peptide.<\/p>\n<p>Finally, literature about a reference molecule does not document the identity or purity of a supplied batch. Those require batch-linked analytical records. Experimental planning should keep compound identity, primary literature, review literature, model selection and batch documentation as separate, traceable layers.<\/p>\n<h2>Sources<\/h2>\n<ol>\n<li>Hashimoto Y, et al. <em>Proceedings of the National Academy of Sciences of the United States of America<\/em>. 2001;98(11):6336-41. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/11371646\/\" target=\"_blank\" rel=\"noopener\">PMID 11371646<\/a>. DOI: 10.1073\/pnas.101133498. Primary work; cultured neuronal cells.<\/li>\n<li>Lee C, et al. <em>Cell Metabolism<\/em>. 2015;21(3):443-54. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25738459\/\" target=\"_blank\" rel=\"noopener\">PMID 25738459<\/a>. DOI: 10.1016\/j.cmet.2015.02.009. Primary work; preclinical mouse and cell models.<\/li>\n<li>Cobb LJ, et al. <em>Aging (Albany NY)<\/em>. 2016;8(4):796-809. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27070352\/\" target=\"_blank\" rel=\"noopener\">PMID 27070352<\/a>. DOI: 10.18632\/aging.100943. Primary work; in-vitro cell models and an in-vivo clamp study, species not stated in the abstract.<\/li>\n<li>Kim KH, et al. <em>Cell Metabolism<\/em>. 2018;28(3):516-524.e7. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29983246\/\" target=\"_blank\" rel=\"noopener\">PMID 29983246<\/a>. DOI: 10.1016\/j.cmet.2018.06.008. Primary work; cellular and molecular models.<\/li>\n<li>Reynolds JC, et al. <em>Nature Communications<\/em>. 2021;12(1):470. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33473109\/\" target=\"_blank\" rel=\"noopener\">PMID 33473109<\/a>. DOI: 10.1038\/s41467-020-20790-0. Primary work; cell and mouse models plus a human exercise component with endogenous-expression measurement.<\/li>\n<li>Yang B, et al. <em>Biochimica et Biophysica Acta. Molecular Basis of Disease<\/em>. 2021;1867(6):166126. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33722744\/\" target=\"_blank\" rel=\"noopener\">PMID 33722744<\/a>. DOI: 10.1016\/j.bbadis.2021.166126. Primary work; C2C12 myotubes and high-fat-diet-induced obese mice.<\/li>\n<li>Yen K, et al. <em>Trends in Genetics<\/em>. 2025;41(2):132-145 (e-pub 2024 Dec 16). <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39690001\/\" target=\"_blank\" rel=\"noopener\">PMID 39690001<\/a>. DOI: 10.1016\/j.tig.2024.11.010. Review.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Mitochondrial peptides are peptides encoded by open reading frames in mitochondrial DNA and therefore outside the nuclear genome. Humanin, reported in 2001, and MOTS-c, reported in 2015, are the two earliest named representatives covered by this source set. Their shared genetic origin defines a research class; it does not make their structures, experimental roles or [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":0,"parent":445,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-462","page","type-page","status-publish","hentry"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/pages\/462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/types\/page"}],"replies":[{"embeddable":true,"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/comments?post=462"}],"version-history":[{"count":0,"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/pages\/462\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/pages\/445"}],"wp:attachment":[{"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/media?parent=462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}